A randomized, open label, multi-center, active-comparator study to assess the efficacy, safety and tolerability of ofatumumab 20mg in relapsing-remitting multiple sclerosis (SOSTOS)
A randomized, open label, multi-center, active-comparator study to assess the efficacy, safety and tolerability of ofatumumab 20mg sc monthly versus continued current therapy in relapsing-remitting multiple sclerosis after elevation of serum neurofilament light levels (SOSTOS)
-
Clinical Trial Information
Trial Contact: Carlo, Charlene S; Monserrate, Francheska
Trial Phone: 321.841.1324 ; 321-841-4717
-
IRB No: W22.092.04
Protocol Abbrev: SOSTOS
Principal Investigator: Amparo Gutierrez, MD, FAAN
Phase: Drug: Phase IV
Age Group: Adult
Secondary Protocol No: COMB157GUS09
Treatment: Ofatumumab
Therapies Involved: Medication
ClinicalTrials.gov ID: NCT05090371
-
Objective
To determine if patients who have not had a relapse in the past year would benefit from switching to ofatumumab
-
Key Eligibility
RRMS diagnosis, on a current disease-modifying therapy, no relapse within 6 months prior to screening, and willing to use wearable device
